Trial Profile
Safety and Efficacy of Switching a Stable Combined Antiretroviral Therapeutic Regimen to Atazanavir With Ritonavir Plus Lamivudine in Treatment Experienced HIV Positive Patients With Full and Stable Virological Suppression
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections; HIV-1 infections
- Focus Therapeutic Use
- Acronyms ATLAS; ATLAS 2; ATLAS-M
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 Results of a substudy (n=139) evaluating the impact of the simplification to atazanavir/ritonavir plus lamivudine dual therapy at 48 weeks on soluble markers of systemic inflammation published in the Journal of Antimicrobial Chemotherapy
- 10 Mar 2017 Results of substudy(n=201) assessing the impact of the atazanavir/ritonavir+lamivudine dual therapy versus the three-drug continuing atazanavir/ritonavir-based therapy on the HIV-1 cellular reservoir after 48 weeks, published in the Journal of Antimicrobial Chemotherapy.